Cymbalta Sales Way Up
Eli Lilly announced its third quarter results today. Cymbalta sales are way up:
“Lilly’s biggest drug, Zyprexa, posted sales of $1.2 billion, up 2.8%. Higher selling prices offset lower demand in the U.S. Demand increased outside the U.S. Sales of antidepressant Cymbalta rose 10% to $790 million.”
A 10 percent increase over the same quarter last year is pretty significant. While I’m not clear on whether Lilly upped Cymbalta prices in the last year (which would account for a portion of the revenue increase if they had), it looks as though more scrips for this tricky anti-depressant are being written. Whether they are for depression or for pain indications isn’t clear to me at all.
It looks like Cymbalta could top $3 billion in sales this year.
Related posts:
Posted in Furious Seasons